Burshtein Joshua, Armstrong April, Chow May, DeBusk Lauren, Gottlieb Alice B, Gold Linda Stein, Korman Neil J, Lio Peter, Merola Joseph, Rosmarin David, Rosenberg Angela, Van Voorhees Abby, Lebwohl Mark
Department of Dermatology, University of Illinois Chicago, Chicago, Illinois.
Division of Dermatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
J Am Acad Dermatol. 2025 Apr;92(4):807-815. doi: 10.1016/j.jaad.2024.12.016. Epub 2024 Dec 19.
Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
A comprehensive literature search was completed on July 19, 2024, using the keywords "psoriasis," "obesity," "efficacy," "treatments," and "therapies." A panel of 11 dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned.
The literature search produced 500 articles. A screening of the studies resulted in 22 articles that met criteria. The panel unanimously voted to adopt 10 consensus statements and recommendations, 6 were given a strength of "A," 2 were given a strength of "B," and 2 were given a strength of "C."
Psoriasis and obesity have a strong association. Obesity decreases efficacy of biologics and may decrease efficacy and potentiate side effects of conventional therapies. It also impacts drug survival. Weight control is a vital component of caring for patients with psoriasis and the number of therapeutic options available is rising.
银屑病是一种慢性炎症性皮肤病，常与肥胖相关。银屑病疗法在肥胖患者中可能效果较差。本专家共识小组的目的是评估肥胖与银屑病疗法疗效之间的关系，从而优化患者护理。
2024年7月19日完成了一项全面的文献检索，使用的关键词为“银屑病”“肥胖”“疗效”“治疗”和“疗法”。由11名在银屑病治疗方面具有丰富专业知识的皮肤科医生组成的小组聚集在一起，对文章进行评审并制定共识声明。采用改良的德尔菲法批准每条声明，并给出推荐强度。
文献检索共产生500篇文章。对这些研究进行筛选后，有22篇文章符合标准。该小组一致投票通过了10条共识声明和建议，其中6条的推荐强度为“A”，2条为“B”, 2条为“C”。
银屑病与肥胖密切相关。肥胖会降低生物制剂的疗效，并可能降低传统疗法的疗效并增强其副作用。它还会影响药物留存率。体重控制是银屑病患者护理的重要组成部分，并且可用的治疗选择数量正在增加。
